Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma
Pharmacy Times,
Précis Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity…
Caring for a Patient Undergoing CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
Oncology Nursing News,
Nicole McEntee, BSN, RN, OCN, BMTCN The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple…
Recap: Mitigation of CRS and ICANS During Bispecific Treatment in Multiple Myeloma
Cancer Network,
CancerNetwork® hosted a Training Academy program focused on monitoring cytokine release syndrome (CRS) and immune effector cell–a…
Preparing Patients for CAR T-Cell Therapy With Confidence
Oncology Nursing News,
Over the past 6 years, a form of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy has emerged as a…